JPWO2023059598A5 - - Google Patents
Info
- Publication number
- JPWO2023059598A5 JPWO2023059598A5 JP2024520702A JP2024520702A JPWO2023059598A5 JP WO2023059598 A5 JPWO2023059598 A5 JP WO2023059598A5 JP 2024520702 A JP2024520702 A JP 2024520702A JP 2024520702 A JP2024520702 A JP 2024520702A JP WO2023059598 A5 JPWO2023059598 A5 JP WO2023059598A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- alkyl
- kras
- shp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252561P | 2021-10-05 | 2021-10-05 | |
| US63/252,561 | 2021-10-05 | ||
| PCT/US2022/045623 WO2023059598A1 (en) | 2021-10-05 | 2022-10-04 | Combination therapies of kras g12d inhibitors with shp-2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024540839A JP2024540839A (ja) | 2024-11-06 |
| JP2024540839A5 JP2024540839A5 (https=) | 2025-10-10 |
| JPWO2023059598A5 true JPWO2023059598A5 (https=) | 2025-10-10 |
Family
ID=85803689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520702A Pending JP2024540839A (ja) | 2021-10-05 | 2022-10-04 | Ｋｒａｓ ｇ１２ｄ阻害剤とｓｈｐ－２阻害剤との併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240423984A1 (https=) |
| EP (1) | EP4412719A4 (https=) |
| JP (1) | JP2024540839A (https=) |
| KR (1) | KR20240073114A (https=) |
| CN (1) | CN118401254A (https=) |
| WO (1) | WO2023059598A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024543879A (ja) * | 2021-11-24 | 2024-11-26 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｋｒａｓ変異型タンパク質の小分子阻害剤 |
| JP2025518795A (ja) * | 2022-06-03 | 2025-06-19 | ベラステム・インコーポレーテッド | 異常な細胞成長を処置するための併用療法 |
| JP2025523101A (ja) * | 2022-07-12 | 2025-07-17 | メッドシャイン ディスカバリー インコーポレイテッド | ピペラジン架橋置換複素環ピリミジン系化合物 |
| AU2024329738A1 (en) * | 2023-08-22 | 2026-04-09 | Sanofi | 2-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1,3,5-triazine derivatives as kras g12d inhibitors for the treatment of cancer |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| AU2024357850A1 (en) | 2023-10-09 | 2026-04-23 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2026080796A1 (en) * | 2024-10-11 | 2026-04-16 | Mirati Therapeutics, Inc. | Mrtx1133 capsule pharmaceutical compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2021076655A1 (en) | 2019-10-15 | 2021-04-22 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| EP4225383A4 (en) * | 2020-10-08 | 2024-12-11 | Kumquat Biosciences Inc. | MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES |
| WO2022187528A1 (en) * | 2021-03-05 | 2022-09-09 | Nikang Therapeutics, Inc | Quinazoline amine derivatives as kras inhibitors |
| WO2023284730A1 (en) | 2021-07-14 | 2023-01-19 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
-
2022
- 2022-10-04 KR KR1020247015004A patent/KR20240073114A/ko active Pending
- 2022-10-04 US US18/694,921 patent/US20240423984A1/en active Pending
- 2022-10-04 WO PCT/US2022/045623 patent/WO2023059598A1/en not_active Ceased
- 2022-10-04 CN CN202280077626.5A patent/CN118401254A/zh active Pending
- 2022-10-04 EP EP22879176.0A patent/EP4412719A4/en active Pending
- 2022-10-04 JP JP2024520702A patent/JP2024540839A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025000632A5 (https=) | ||
| JP2025000629A5 (https=) | ||
| CN115154467B (zh) | 治疗肝纤维化的方法 | |
| AU2017246460B2 (en) | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | |
| JP2022500384A5 (https=) | ||
| JP2022500388A5 (https=) | ||
| JPWO2023059598A5 (https=) | ||
| JPWO2020118066A5 (https=) | ||
| JP2019516718A5 (https=) | ||
| JPWO2023059597A5 (https=) | ||
| FI3849537T3 (fi) | Yhdistelmäterapioita | |
| US11401278B2 (en) | Macrocyclic indole derivatives | |
| EP2793899A1 (en) | Hypoxia activated prodrugs and mtor inhibitors for treating cancer | |
| CA2551737A1 (en) | Helix 12 directed steroidal pharmaceutical products | |
| JPWO2021061749A5 (https=) | ||
| JP2011513475A5 (https=) | ||
| JP2017518360A5 (https=) | ||
| JPWO2020055755A5 (https=) | ||
| IL311834A (en) | Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods | |
| JPWO2020055760A5 (https=) | ||
| RU2009102275A (ru) | Органические соединения | |
| US20150005354A1 (en) | Combination Therapy With Parp Inhibitors | |
| JPWO2020055761A5 (https=) | ||
| JP2010531322A (ja) | アントラニルアミドピリジンウレア及びベンズアミド誘導体の相乗組合せ | |
| JP2019516763A (ja) | ［８−（フェニルスルホニル）−３，８−ジアザビシクロ［３．２．１］オクタ−３−イル］（１ｈ−１，２，３−トリアゾール−４−イル）メタノン |